DA
FULC icon

Denali Advisors’s Fulcrum Therapeutics FULC Stock Holding History

Denali Advisors’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-27,100
Closed -$256K – 288
2024
Q1 		$256K Sell
27,100
-30,700
-53% -$274K 0.08% 204
2023
Q4 		$390K Sell
57,800
-12,800
-18% -$56.8K 0.12% 171
2023
Q3 		$313K Buy
+70,600
New +$309K 0.11% 186
2022
Q3 		– Sell
-3,900
Closed -$19K – 376
2022
Q2 		$19K Hold
3,900
– – 0.01% 308
2022
Q1 		$92K Hold
3,900
– – 0.04% 202
2021
Q4 		$69K Buy
+3,900
New +$77.3K 0.03% 221

Other funds holding FULC

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Denali Advisors's FULC Position: Q2 2024 in Review

Denali Advisors sold out of Fulcrum Therapeutics (FULC) in Q2 2024, closing a stake of 27,100 shares — an estimated $256K sold.

Denali Advisors first reported a position in FULC in Q4 2021 and held it in 6 quarters. The position peaked at $390K in Q4 2023. 121 funds tracked by Wall St. Rank hold FULC as of Q2 2024.

  • Denali Advisors reported no remaining Fulcrum Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Denali Advisors sold 27,100 Fulcrum Therapeutics shares in Q2 2024, an estimated $256K.
  • Denali Advisors first reported a position in Fulcrum Therapeutics in Q4 2021 and held it in 6 quarters.
  • Denali Advisors's Fulcrum Therapeutics position peaked at $390K in Q4 2023.
  • 121 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2024.

Based on Denali Advisors's 13F filing for Q2 2024, filed 9 Aug 2024.